Overview

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Status:
Terminated
Trial end date:
2020-10-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of delafloxacin administered as IV and oral formulation in comparison with Best Available Therapy (BAT) in patients with superficial or deep incisional surgical site infection following a cardiothoracic/related leg or abdominal surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Menarini Group
Treatments:
Delafloxacin
Fluoroquinolones
Linezolid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam
Tigecycline
Vancomycin